New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
07:59 EDTNVAXNovavax price target raised to $10 from $4 at Ladenburg
Ladenburg believes that Novavax' balance sheet and opportunity to raise capital puts the company in position to fund both late-stage development and commercialization of its RSV vaccine in the U.S. Ladenburg thinks building a commercial organization is more attractive than partnering for the vaccine in the U.S. despite the higher risk and raised its price target on Novavax to $10 from $4.
News For NVAX From The Last 14 Days
Check below for free stories on NVAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for NVAX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use